Bank of America Corp DE Acquires 9,077 Shares of Theravance Biopharma Inc (TBPH)

Bank of America Corp DE raised its holdings in shares of Theravance Biopharma Inc (NASDAQ:TBPH) by 89.4% in the fourth quarter, HoldingsChannel reports. The firm owned 19,233 shares of the biopharmaceutical company’s stock after buying an additional 9,077 shares during the period. Bank of America Corp DE’s holdings in Theravance Biopharma were worth $492,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. FNY Investment Advisers LLC bought a new stake in Theravance Biopharma during the 4th quarter valued at $42,000. Bank of New York Mellon Corp increased its stake in Theravance Biopharma by 1.2% during the 4th quarter. Bank of New York Mellon Corp now owns 208,117 shares of the biopharmaceutical company’s stock valued at $5,326,000 after purchasing an additional 2,547 shares in the last quarter. Quantamental Technologies LLC bought a new stake in Theravance Biopharma during the 4th quarter valued at $102,000. Northern Trust Corp increased its stake in Theravance Biopharma by 0.8% during the 4th quarter. Northern Trust Corp now owns 550,796 shares of the biopharmaceutical company’s stock valued at $14,095,000 after purchasing an additional 4,274 shares in the last quarter. Finally, Citigroup Inc. increased its stake in Theravance Biopharma by 258.5% during the 4th quarter. Citigroup Inc. now owns 6,481 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 4,673 shares in the last quarter. Institutional investors and hedge funds own 85.14% of the company’s stock.

In other news, SVP Sharathchandra S. Hegde sold 9,033 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $24.71, for a total value of $223,205.43. Following the completion of the sale, the senior vice president now owns 270,134 shares in the company, valued at approximately $6,675,011.14. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Donal O’connor sold 4,000 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $20.46, for a total transaction of $81,840.00. Following the completion of the sale, the director now owns 30,244 shares of the company’s stock, valued at approximately $618,792.24. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

NASDAQ TBPH opened at $19.84 on Tuesday. Theravance Biopharma Inc has a 1 year low of $19.77 and a 1 year high of $35.48. The firm has a market capitalization of $1.13 billion, a PE ratio of -4.97 and a beta of 1.68.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.14). Theravance Biopharma had a negative return on equity of 2,632.27% and a negative net margin of 388.61%. The firm had revenue of $5.34 million during the quarter, compared to the consensus estimate of $16.45 million. On average, research analysts expect that Theravance Biopharma Inc will post -4.74 earnings per share for the current year.

A number of brokerages have commented on TBPH. BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $29.00 price target for the company in a research note on Monday, February 11th. Cantor Fitzgerald began coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a “buy” rating and a $55.00 target price for the company. Finally, ValuEngine lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $43.40.

ILLEGAL ACTIVITY NOTICE: “Bank of America Corp DE Acquires 9,077 Shares of Theravance Biopharma Inc (TBPH)” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/21/bank-of-america-corp-de-acquires-9077-shares-of-theravance-biopharma-inc-tbph.html.

Theravance Biopharma Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Further Reading: Dollar Cost Averaging

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.